Protalix BioTherapeutics, Inc. (PLX): Net Income
-$6.60M
Year ended 2025-12-31
$18.95M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.60M | n/m | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $2.93M | -64.7% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $8.31M | n/m | 2026-03-18, From 2023-01-01 |
| 2022-12-31 | -$14.93M | n/m | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | -$27.58M | n/m | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | -$6.52M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$18.28M | n/m | 2022-03-31, From 2019-01-01 |
| 2018-12-31 | -$26.46M | n/m | 2021-03-30, From 2018-01-01 |
| 2017-12-31 | -$83.44M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$29.36M | n/m | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $58.04M | n/m | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | -$29.94M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$27.79M | n/m | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | -$11.62M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$36.53M | n/m | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | -$29.00M | n/m | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | -$31.44M | n/a | 2012-02-27, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$6.60M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$52.49M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.18M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$9.74M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$437.99M | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$160.06M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$119.72M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $22.37M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$122.93M | n/m |
Compare PLX, IVVD, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗